Get the Stockscreener App
11.13
2.41%
-0.28
Korro Bio Inc stock is traded at $11.13, with a volume of 15,634.
It is down -2.41% in the last 24 hours and down -4.83% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$11.41
Open:
$11.26
24h Volume:
15,634
Relative Volume:
0.06
Market Cap:
$110.32M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.8918
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-3.17%
1M Performance:
-4.83%
6M Performance:
-69.11%
1Y Performance:
-53.06%
1-Day Range:
$11.04
$11.26
1-Week Range:
$11.04
$14.79
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
11.12 | 113.19M | 6.39M | -117.26M | -79.08M | -12.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.60 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.21 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.06 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.65 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.62 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio raises $85 million in private equity financing By Investing.com - Investing.com Nigeria
Korro Bio Stock Gains After Tough 2025New Drug Candidate, Analyst Upgrades Boost Outlook - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
RBC Capital Keeps Their Hold Rating on Korro Bio (KRRO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Health Catalyst (HCAT) - The Globe and Mail
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability - simplywall.st
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement - Stock Titan
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence - Investing.com Canada
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot - Investing.com Nigeria
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot By Investing.com - Investing.com UK
Insider Buying: New Enterprise Associates 17, L.P. Acquires Addi - GuruFocus
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Korro Bio investor buys $2.3 million in KRRO stock By Investing.com - Investing.com
Advancing Genetic Medicines with RNA Editing: Inside the OPERA Platform and Therapeutic Strategies - Minichart
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates - MSN
Baskett Forest buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million By Investing.com - Investing.com South Africa
NEA 17 fund tied to Korro Bio (KRRO) buys 450K shares and warrants - Stock Titan
Insider fund tied to Carmen Chang boosts Korro Bio (KRRO) stake with 450,045 buys - Stock Titan
Korro 10-K: $6.4M Collaboration Revenue; $(12.48) EPS on $(117.3)M Net Loss - TradingView
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
New RNA edit drug, $85M cash boost give Korro Bio runway to 2028 - Stock Titan
Korro Bio, Inc. (KRRO) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Korro shares jump 17% following $85M private placement financing - MSN
Korro Bio (KRRO) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Korro Secures $85M Lifeline After Trial Setback - National Today
Korro Bio Raises $85 Million in Oversubscribed PIPE Financing to Advance RNA Editing Therapies and Extend Cash Runway into 2028 - Minichart
Korro Bio extends cash runway after trial fail, layoffs - The Business Journals
Korro Announces $85 Million Private Placement - citybiz
Korro Bio prices 4.5M shares at $11.11 in private placement - TipRanks
Korro Announces Oversubscribed $85 Million Private Placement - Bitget
Korro Bio Announces Oversubscribed $85M PIPE Financing - TipRanks
Korro stock surges 17% on $85M private placement financing By Investing.com - Investing.com India
Korro Bio raises $85 million in private equity financing - Investing.com
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro stock surges 17% on $85M private placement financing - Investing.com
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Korro Bio, Inc. $KRRO Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Bond Watch: Does Korro Bio Inc have pricing powerJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Winners Losers: Should you avoid Korro Bio Inc stock right nowWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts - Defense World
KRRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KRRO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bond Watch: What is the next catalyst for Korro Bio IncTrade Volume Report & Precise Swing Trade Alerts - baoquankhu1.vn
Profit Recap: Will Korro Bio Inc benefit from green energy policiesQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Korro Bio (KRRO) price target increased by 12.61% to 19.53 - MSN
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SANDELL SCOTT D | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| New Enterprise Associates 17, | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Chang Carmen | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| BASKETT FOREST | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Mathers Edward T | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Makhzoumi Mohamad | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Walker Paul Edward | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Florence Anthony A. Jr. | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
0.15%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):